Nasdaq · Healthcare
NewAmsterdam Pharma Co N.V. (NAMS)
As-reported financials and recent SEC filings for NewAmsterdam Pharma Co N.V., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$22.5M
Net income
$-203.8M
Net margin
—
Diluted EPS
$-1.72
ROE
-29.8%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2023 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $22.5M | $45.6M | $14.1M | $102.7M | — |
| Gross profit | — | — | — | — | — |
| Operating income | $-225.7M | $-176.3M | $-183.0M | $-3.6M | $-35.0M |
| Net income | $-203.8M | $-241.6M | $-176.9M | $-22.6M | $-41.8M |
| Diluted EPS | $-1.72 | $-2.56 | $-2.15 | $-0.30 | $-0.95 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-24
View on EDGAR →S-82026-06-05
View on EDGAR →SCHEDULE 13G/A2026-06-04
View on EDGAR →8-K2026-06-03
View on EDGAR →42026-05-27
View on EDGAR →1442026-05-26
View on EDGAR →SCHEDULE 13D/A2026-05-14
View on EDGAR →8-K2026-05-07
View on EDGAR →Largest Healthcare peers
Go deeper on NAMS
Search NewAmsterdam Pharma Co N.V.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.